Usnoflast well tolerated, shows signs of efficacy in ALS patients
An experimental oral treatment from Zydus Lifesciences was well tolerated at all tested doses and showed signs of slowing…
Articles by Andrea Lobo, PhD
Zydus’ usnoflast wins FDA’s fast track drug status for treating ALS
The U.S. Food and Drug Administration (FDA) has granted fast track status to usnoflast, Zydus Lifesciences’ experimental oral inhibitor,…
ALS Network collaborates on $300K drug-repurposing study
The ALS Network will support a collaborative research effort, at California’s Lawrence Livermore National Laboratory, that will use electronic…
Neuronata-R improved function, survival in slow-progressing ALS
Neuronata-R (lenzumestrocel), an investigational stem cell therapy from Corestemchemon significantly improved function and reduced markers of nerve cell damage…
Crunch Fitness hosts exercise event for Augie’s Quest to Cure ALS
Crunch Fitness will host a nationwide fundraising event to support Augie’s Quest to Cure ALS, an organization dedicated…
Prilenia partners with Ferrer to advance pridopidine for ALS
Prilenia Therapeutics has entered a collaboration and license agreement with Ferrer to codevelop and commercialize pridopidine, its…
Trial will use digital biomarkers to assess short-term ALS progression
Verge Genomics has identified multiple digital clinical biomarkers that can be used to assess short-term disease progression in the…
ALS patient treated with TRE-515 in expanded access program
A patient with late-stage amyotrophic lateral sclerosis (ALS) was treated with TRE-515, Trethera’s investigational therapy, under a U.S.
FDA approves study of SNUG01 gene therapy for ALS patients
The U.S. Food and Drug Administration (FDA) has authorized Sineugene Therapeutics to begin a Phase 1/2a trial of its…
Californians can help fund ALS research through tax contributions
People living in California can help fund amyotrophic lateral sclerosis (ALS) research when filing their state taxes. The…